加载中
NASDAQHealthcareBiotechnology
最新数据
US$7.4704
−US$0.3496 · -4.47%
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
常规交易时段
US$7.4704
−US$0.3496 · -4.47%
盘中时间采用ET。市场数据可能有所延迟。
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
日内区间
当前US$7.4704
52周区间
当前US$7.4704
盘中时间采用ET。市场数据可能有所延迟。
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
日内区间
当前US$7.4704
52周区间
当前US$7.4704
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1.58亿 USD | 1.25亿 USD | 8614万 USD | 8227.4万 USD | 5110万 USD |
| 销售、一般及管理费用 | 2100.1万 USD | 1774.1万 USD | 1882.1万 USD | 2471.4万 USD | 2039.1万 USD |
| 营业费用 | 1.79亿 USD | 1.42亿 USD | 1.05亿 USD | 1.07亿 USD | 7149.1万 USD |
| 利息收入 | 1622.4万 USD | 1268.2万 USD | 832.5万 USD | 222.8万 USD | 44.2万 USD |
| 折旧和摊销 | 49万 USD | 39.3万 USD | 37.7万 USD | 35.7万 USD | 16.3万 USD |
| 营业利润 | −1.79亿 USD | −1.42亿 USD | −1.05亿 USD | −1.07亿 USD | −7149.1万 USD |
| 净利润 | −1.62亿 USD | −1.29亿 USD | −9665.5万 USD | −1.05亿 USD | −7109.6万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$28.33
上涨空间 279.23%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2723.58万0.00%2.3万亿 USD0.03%US$381.48-0.12%
State Street SPDR S&P Biotech ETFXBI1700.15万0.17%98.74亿 USD0.35%US$151.66-1.37%
iShares Russell 2000 ETFIWM1601.37万0.02%787.4亿 USD0.19%US$278.3-0.23%
Vanguard Extended Market ETFVXF687.92万0.01%954亿 USD0.05%US$234.19-0.34%
Vanguard Russell 2000 ETFVTWO469.92万0.03%180亿 USD0.06%US$112.42-0.22%
Dimensional - US Small Cap ETFDFAS446.39万0.01%338.69亿 USD0.31%US$78.405+0.07%
iShares Biotechnology ETFIBB426.65万0.04%108.2亿 USD0.44%US$204.11-1.15%
Fidelity Enhanced Small Cap ETFFESM369.04万0.06%64.1亿 USD0.28%US$45.35-0.24%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
